<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">57278</article-id><article-id pub-id-type="doi">10.7554/eLife.57278</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Short Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-180707"><name><surname>Rossi</surname><given-names>Gian Paolo</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7963-0931</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-180965"><name><surname>Sanga</surname><given-names>Viola</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-97155"><name><surname>Barton</surname><given-names>Matthias</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor3">*</xref><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><institution content-type="dept">Department  of Medicine-DIMED - Hypertension Unit</institution>, <institution>University of Padova</institution>, <addr-line><named-content content-type="city">Padova</named-content></addr-line>, <country>Italy</country></aff><aff id="aff2"><institution>University of Zurich</institution>, <addr-line><named-content content-type="city">Zurich</named-content></addr-line>, <country>Switzerland</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-73636"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Reviewing editor</role><aff><institution>Icahn School of Medicine at Mount Sinai</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>gianpaolo.rossi@unipd.it</email> (GR);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>sangaviola.md@gmail.com</email> (VS);</corresp><corresp id="cor3"><label>*</label>For correspondence: <email>barton@access.uzh.ch</email> (MB);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>06</day><month>04</month><year>2020</year></pub-date><volume>9</volume><elocation-id>e57278</elocation-id><history><date date-type="received"><day>26</day><month>03</month><year>2020</year></date><date date-type="accepted"><day>03</day><month>04</month><year>2020</year></date></history><permissions><copyright-statement>Â© 2020, Rossi et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Rossi et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-57278-v1.pdf"/><abstract><p>The discovery that SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) RNA binds to the angiotensin converting enzyme (ACE)-2, which is highly expressed in the lower airways, explained why SARS-CoV-2 causes acute respiratory distress syndrome (ARDS) and respiratory failure. After this, news spread that ACEis and ARBs would be harmful in SARS-CoV-2-infected subjects. To the contrary, compelling evidence exists that the ACE-1/angiotensin(Ang)II/ATR-1 pathway is involved in SARS-CoV-2-induced ARDS, while the ACE-2/Ang(1-7)/ATR2/MasR pathway counteracts the harmful actions of AngII in the lung. A reduced ACE-1/ACE-2 ratio is, in fact, a feature of ARDS that can be rescued by human recombinant ACE-2 and Ang(1-7) administration, thus preventing SARS-CoV-2-induced damage to the lung. Based on the current clinical evidence treatment with ACE-inhibitors I (ACEis) or angiotensin receptor blockers (ARBs) continues to provide cardiovascular and renal protection in patients diagnosed with COVID-19. Discontinuing these medications may therefore be potentially harmful in this patient population.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Viruses</kwd></kwd-group><funding-group><funding-statement>The authors declare that there was no funding for this work.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Matthias Barton, Senior Editor, <italic>eLife</italic>.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>N/A</p></sec></sec></back></article>